产品名称

CHIR 99021 - CT 99021

产品货号

Axon 1386 CAS [252917-06-9] MF C22H18Cl2N8MW 465.34 Purity: 99% Soluble in 0.1N HCl(aq) and DMSO Description Very potent and specific glycogen synthase kinase GSK-3 inhibitor; highly recommended tool. * CHIR 99021 and PD 0325901 (Axon 1408) are often used together as 2i in stem cell research (Axon 2128). CHIR 99021 is also available as the water soluble HCl salt (Axon 2435) *Promotion

产品价格

现货询价，电话：010-67529703

产品规格

产品品牌

axonmedchem

产品概述

产品详情

CHIR 99021 - CT 99021

Based on 3890 reference(s) in Google Scholar 10 10 3890

Axon 1386

CAS [252917-06-9]

MF C22H18Cl2N8
MW 465.34

Purity: 99%
Soluble in 0.1N HCl(aq) and DMSO

CHIR 99021

Description

Very potent and specific glycogen synthase kinase GSK-3 inhibitor; highly recommended tool. * CHIR 99021 and PD 0325901 (Axon 1408) are often used together as 2i in stem cell research (Axon 2128).

CHIR 99021 is also available as the water soluble HCl salt (Axon 2435)

*Promotion: CHIR 99021 is also part of Inhibitor Set(s):

Axon 2128	Axon 2129	Axon 2130	Axon 5005
Axon 5006	Axon 5007	Axon 5010

Prime Source Information:
CHIR 99021 from Axon Medchem has been procured by many labs as drug standard for generating reliable and reproducible biological data, evidenced by many recent publications. It is pure not only chemically but also biologically.

KEYWORDS: CHIR 99021 | CT 99021 | CHIR99021 | CT99021 | Supplier | CAS [252917-06-9] | [1782235-14-6] | [1797989-42-4] | GSK3 inhibitor | GSK 3 | GSK3 | Axon 1386 | glycogen synthase kinase | stem cell | pluripotent | differentitaion | proliferation | dedifferentiation | cardiac

C Tong et al. Generating gene knockout rats by homologous recombination in embryonic stem cells. Nature Protocols 2011, 6, 827–844.

M Kawamata and T Ochiya. Generation of genetically modified rats from embryonic stem cells. PNAS 2010, 107(32), 14223-14228.

MY Chang et al. Direct Reprogramming of Rat Neural Precursor Cells and Fibroblasts into Pluripotent Stem Cells. PLoS One. 2010, 5(3), e9838.

IM Aparicio et al. Identification and regulation of glycogen synthase kinase-3 during bovine embryo development. Reproduction 2010, 140, 83-92.

B Zimmer et al. Coordinated waves of gene expression during neuronal differentiation of embryonic stem cells as basis for novel approaches to developmental neurotoxicity testing. Cell Death and Differentiation. 2011, 18, 383–395.

Q.L.Ying et al. The ground state of embryonic stem cell self-renewal. Nature. 2008, 453, 519-523.

J. Bain et al. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 2007, 408, 297-315.

D.B. Ring et al. Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003, 52, 588-595.

A.S. Wagman et al. Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes. Curr. Pharm. Des. 2004, 10, 1105-1137.

List of publications using CHIR 99021 (Axon 1386) purchased from Axon Medchem

Cell Signaling & Oncology CNS Diabetes & Metabolism Immunology Pain & Inflammation Stem Cell GSK-3 Wnt-β-Catenin PI3K-Akt-mTOR EC 2.7.11.26

GSK-3 inhibitor

Chemical name

6-{2-[4-(2,4-Dichloro-phenyl)-5-(5-methyl-1H-imidazol-2-yl)-pyrimidin-2-ylamino]-ethylamino}-nicotinonitrile

Parent CAS No.

[252917-06-9]

产品资料